51
|
Shin H, Lee S, Lee K, Choi W, Kim T, Moon H, Kim H, Lee K, Kim E. P012 Systematic review of HPV test [Invader Technology/Real-Time PCR]. BMJ Qual Saf 2013. [DOI: 10.1136/bmjqs-2013-002293.128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
52
|
Yap YS, Cornelio GH, Devi BCR, Khorprasert C, Kim SB, Kim TY, Lee SC, Park YH, Sohn JH, Sutandyo N, Wong DWY, Kobayashi M, Landis SH, Yeoh EM, Moon H, Ro J. Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival. Br J Cancer 2012; 107:1075-82. [PMID: 22918394 PMCID: PMC3461152 DOI: 10.1038/bjc.2012.346] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2012] [Revised: 07/10/2012] [Accepted: 07/13/2012] [Indexed: 11/28/2022] Open
Abstract
BACKGROUND In Asia, large-scale studies on anti-HER2 treatment in HER2-positive breast cancer patients with brain metastases are limited. We studied the treatment patterns of these patients in Asia to evaluate the impact of anti-HER2 treatment on the time to occurrence of brain metastases (TTBM) and survival after brain metastasis (BM). METHODS A retrospective study of HER2-positive breast cancer patients diagnosed with BM between January 2006 and December 2008 in six Asian countries was conducted. Demographics, tumour characteristics, treatment details, and events dates were collected from medical records. RESULTS Data from 280 patients were analysed. Before BM, 63% received anti-HER2 treatment. These patients had significantly longer TTBM than those without anti-HER2 treatment (median 33 vs 19 months; P<0.002). After BM, 93% received radiotherapy, 57% received chemotherapy, and 41% received anti-HER2 treatment (trastuzumab and/or lapatinib). Use of both anti-HER2 agents, primarily sequentially, after BM demonstrated the longest survival after BM and was associated with a significant survival benefit over no anti-HER2 treatment (median 26 vs 6 months; hazard ratio 0.37; 95% CI 0.19-0.72). CONCLUSION Anti-HER2 treatment before BM was associated with longer TTBM. Anti-HER2 treatment after BM was associated with a survival benefit, especially when both trastuzumab and lapatinib were utilised.
Collapse
|
53
|
Moon H, Natavio M, Moore K, Lou M, Besinque K, Johnson K, Opper N, Bender N, Frausto S, Segall-Gutierrez P. Factors influencing pharmacy students' likelihood of recommending oral emergency contraception. Contraception 2012. [DOI: 10.1016/j.contraception.2012.05.112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
54
|
Ahmad RT, Nguyen TV, Shim W, Vigneswaran S, Moon H, Kandasamy J. Effluent organic matter removal by Purolite®A500PS: Experimental performance and mathematical model. Sep Purif Technol 2012. [DOI: 10.1016/j.seppur.2012.06.025] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
55
|
Suh B, Park Y, Kim Y, Chung P, Moon H, Yoon W, Shim D, Kim S. 43. Neurolymphomatosis mimicking bell’s palsy. Clin Neurophysiol 2012. [DOI: 10.1016/j.clinph.2011.11.125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
56
|
Natavio M, Moore K, Segall-Gutierrez P, Moon H, Besinque K, Opper N, Bender N, Taylor D, Johnson K. Emergency contraception skills workshop for first-year pharmacy students. Contraception 2012. [DOI: 10.1016/j.contraception.2011.11.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
57
|
Ahn SK, Moon H, Ko E, Kim JS, You JM, Shin H, Han W, Noh D. Chemotherapy-induced amennorrhea: Predictive markers of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.27_suppl.281] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
281 Background: There is controversy about the benefit of chemotherapy-induced amenorrhea (CIA) in breast cancer. We investigated significance of CIA after neoadjuvant chemotherapy for predicting response to neoadjuvant chemotherapy in breast cancer patients. Methods: We reviewed the records of 198 premenopausal patients with breast cancer treated with neoadjuvant chemotherapy between January 2005 and December 2010. Chemotherapy-induced amenorrhea (CIA) was defined as serum FSH level ≥40 IU/L after completion of all scheduled neoadjuvant chemotherapy and prior to definitive surgery. Results: Among 198 breast cancer patients, 132 pts (66.7%) developed CIA after neoadjuvant chemotherapy. 156 pts (78%) underwent DA chemotherapy. The age of CIA patients was older than non-CIA patients (41.55±5.55 vs. 38.27± 6.86 years, p=0.001). The incidence of CIA after neoadjuvant chemotherapy was significantly higher in responder group (responder vs. nonresponder: 87 pts (74.4%) vs. 45 pts (55.6%); p=0.006). Additionally, FSH level after all scheduled neoadjuvant chemotherapy was significantly higher in responder group (FSH 56.41±32.41 mIU/ml vs. 45.76±30.31 mIU/ml; p=0.021). In univariate analysis, CIA (p=0.006) and total number of chemotherapy cycle regardless of chemotherapy regimen (p=0.04) were significantly predictive of tumor response. CIA was only significant predictive factor for tumor response after neoadjuvant chemotherapy on multivariate analysis (p=0.012). Conclusions: CIA is independent predictive markers of response to neoadjuvant chemotherapy in locally advanced breast cancer.
Collapse
|
58
|
Jo J, Lee S, Moon H, Park H, Lee T, Choi H. UP-01.211 Comparison Between the Group Who Showed Pain Relief by Alpha Blocker Agent and the Group Who Did Not in Patients with CP/CPPS. Urology 2011. [DOI: 10.1016/j.urology.2011.07.761] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
59
|
Kim H, Han W, Moon H, Ahn SK, Yom CK, Shin H, Noh D. The comparison of the evaluation of axillary lymph node metastasis in breast cancer among PET, chest CT, and ultrasound sonography. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e11567] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
60
|
Yap YS, Devi BC, Khorprasert C, Cornelio GH, Sutandyo N, Yeoh E, Landis S, Kobayashi M, Moon H, Ro J. Survival after brain metastases in Asian patients with HER2+ breast cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.543] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
61
|
Kim HJ, Ahn S, Noh D, Yi OV, Moon H, Ahn SK, Han W. Association of HER2/neu subtype with ipsilateral breast tumor recurrence after breast-conserving surgery in young-age breast cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e21099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
62
|
Shin H, Han W, Moon H, Yom CK, Ahn SK, Kim H, Noh D. Utility of breast MRI for patients with breast-cancer scheduled for breast-conserving surgery. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.1086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
63
|
Lee Y, Lee T, Kim T, Moon H, Cho Y. The Possible Role of Clusterin As a Biomarker Representing Increased Oxidative Stress in Asthma. J Allergy Clin Immunol 2011. [DOI: 10.1016/j.jaci.2010.12.250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
64
|
Ro J, Park S, Kim SB, Kim TY, Im YH, Rha SY, Chung JS, Moon H, Santillana S. Abstract P1-14-04: Clinical Outcomes of Brain Metastasis by Lapatinib (L) and Capecitabine (C) in an Open-Label Expanded Access Study among Korean Patients with HER2 Positive Metastatic Breast Cancer. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p1-14-04] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The L-Expanded Access Program (LEAP) was designed to provide access to L/C for HER2+ patients (pts) who previously received anthracycline, taxane, and trastuzumab. In earlier registration trial, CNS metastases occurred in fewer women receiving L/C therapy compared with C alone. Although L therapy has shown efficacy in brain metastasis (BM), it has not been well elucidated in relationship with the outcomes of systemic disease.
Patients and methods : Enrollment in LEAP lasted between Jan. 2007 and Apr. 2008 at 6 centers in Korea. Exploratory analysis on clinical outcomes of brain metastasis was performed.
Results: Total 187 pts enrolled in LEAP. The median treatment duration of all pts was 19.0 weeks (range, 1.4 — 146.9). The median progression free survival and overall survival (OS) of all pts were 20.0 (95% confidence interval [CI]= 18.6-24.0) and 60.0 (95% CI= 50.3-72.7) weeks, respectively. All patients received prior trastuzumab therapy, and 48.7% received prior capecitabine. Among 58 enrolled pts who had BM diagnosed before start L/C therapy, 55 pts were included for the analysis excluding 3 pts (1-consent withdrawal and 2-<3 weeks trial). Fifteen pts had single BM. Majority were HER2 IHC 3+ or FISH +, and 48% were both ER/PR-. Prior to EAP enrollment, 35 pts underwent whole brain radiation, 10 pts SRS or gamma knife, 3 pts local excision, 1 pt had leptomeningeal disease only receiving intrathecal therapy, and 6 pts did not receive local CNS therapy. Four pts underwent more than one modality of local CNS therapy. Of 50 pts evaluable for response, 9.1%, achieved or remained CR; 45.5% had some degree of shrinkage of BM; 14.5%, no change (SD) ≥6mo; 7.3%, SD <6mo; 14.5% developed PD or recurrence of BM. Median TTP of pts (n=53) with BM on L/C therapy was 30.7 weeks (95% CI=25.0-35.1) and median OS (n=55) was 53.1 weeks (95% CI= 42.3-78.0). From the multivariate analysis, TTP of BM was significantly associated with response of BM (HR, 20.3, 95% CI=7.3-56.0, P<0.001). OS of pts with BM was significantly longer with tumors of ER or PR+ status (HR, 3.10, 95% CI=1.55-6.19, p=0.0014), and who responded in systemic disease and brain (HR, 4.5, 95% CI= 2.2-9.2, P<0.0001). Of remaining 129 pts, 8 pts (6.2%) developed new BM on EAP.
Conclusion: Overall survival of patients with brain metastasis who received lapatinib plus capecitabine was prolonged specifically in responders of both brain and extracranial disease. Patients with hormone receptor positive tumors had longer survival compared with those of hormone receptor negative disease.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P1-14-04.
Collapse
|
65
|
Moon H, Kim J, Park S, Kim Y, Park H, Choi H, Kim S, Choi B, Lee T. UP-2.40: Influence of overactive bladder on falls: study on females aged 40 and older in urban and rural communities. Urology 2010. [DOI: 10.1016/j.urology.2010.07.274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
66
|
Park SJ, Lee KS, Kim SR, Min KH, Moon H, Lee MH, Chung CR, Han HJ, Puri KD, Lee YC. Phosphoinositide 3-kinase δ inhibitor suppresses interleukin-17 expression in a murine asthma model. Eur Respir J 2010; 36:1448-59. [PMID: 20351038 DOI: 10.1183/09031936.00106609] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Phosphoinositide 3-kinases (PI3Ks) contribute to the pathogenesis of asthma by regulating the activation of inflammatory mediators, inflammatory cell recruitment and immune cell function. Recent findings have indicated that PI3Ks also regulate the expression of interleukin (IL)-17, which has been recognised as an important cytokine involved in airway inflammation. In the present study, we investigated a role of PI3Kδ in the regulation of IL-17 expression in allergic airway disease using a murine model of asthma. After ovalbumin inhalation, administration of a selective p110δ inhibitor, IC87114, significantly attenuated airway infiltration of total cells, lymphocytes, neutrophils and eosinophils, as well as airway hyperresponsiveness, and attenuated the increase in IL-17 protein and mRNA expression. Moreover, IC87114 reduced levels of IL-4, -5 and -13, expression of keratinocyte chemoattractant protein and mRNA, and nuclear factor (NF)-κB activity. In addition, a NF-κB inhibitor, BAY 11-7085 substantially reduced the increase in IL-17 protein levels. Our results also showed that inhibition of IL-17 activity with an anti-IL-17 antibody remarkably reduced airway inflammation and hyperresponsiveness. These findings suggest that inhibition of the p110δ signalling pathway suppresses IL-17 expression through regulation of NF-κB activity and, thus, has therapeutic potential in asthma.
Collapse
|
67
|
Lee T, Bae Y, Kim T, Park C, Moon H, Cho Y. Severe Asthma With Longer Disease Duration And Absence Of Rhinitis Is More Likely To Progress To Fixed Airway Obstruction In Korean Asthmatic Patients. J Allergy Clin Immunol 2010. [DOI: 10.1016/j.jaci.2009.12.535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
68
|
Choi DS, Fung AO, Moon H, Villareal G, Chen Y, Ho D, Presser N, Stupian G, Leung M. Detection of neural signals with vertically grown single platinum nanowire-nanobud. JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY 2009; 9:6483-6486. [PMID: 19908553 DOI: 10.1166/jnn.2009.1462] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
We developed a nanoscale neural probing device for in vitro sensing of neural activity. Single vertical platinum (Pt) nanowires were fabricated on a microelectrode array by focused ion beam (FIB)-chemical vapor deposition (CVD) in order to improve the spatial resolution of recording and to minimize damage to the cells. Rat neuroblasts were cultured on the electrode array. Electrodes in contact with cells detected prominent spontaneous electrical activity. Our experiments demonstrate the nanoprobes for the real-time detection of electrophysiological signals in neuronal cells.
Collapse
|
69
|
Tan Y, Han S, Lu Y, Yip C, Sunpaweravong P, Jeong J, Caguioa P, Aggarwal S, Yeoh E, Moon H. 5143 Resource-based data availability for erbB2-driven breast cancer in Asian women: experts' opinion. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71035-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
70
|
Nakano T, Moon H, Nagamine T, Akamatsu S, Nakajima K. Abstract: P929 CHARACTERISTICS OF REMNANT LIPOPROTEINS SEPARATING FROM POSTPRANDIAL NORMOLIPIDEMIC SUBJECTS BY HPLC. ATHEROSCLEROSIS SUPP 2009. [DOI: 10.1016/s1567-5688(09)71050-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
71
|
Moon H, Nakajima K, Kamiyama K, Sakurabayashi I, Nagamine T. Abstract: P406 HIGHER FREQUENCY OF ABNORMAL SERUM ANGIOPOIETIN-LIKE PROTEIN 3 THAN ABNORMAL CHOLESTERYL ESTER TRANSFER PROTEIN IN JAPANESE HYPERALPHALIPOPROTEINEMIC SUBJECTS. ATHEROSCLEROSIS SUPP 2009. [DOI: 10.1016/s1567-5688(09)70701-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
72
|
Huh J, Moon H, Chi H, Chung W. Acute promyelocytic leukemia with i(17)(q10) on G-banding andPML/RARArearrangement by RT-PCR without evidence ofPML/RARArearrangement on FISH. Int J Lab Hematol 2009; 31:372-4. [DOI: 10.1111/j.1751-553x.2008.01040.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
73
|
Han W, Kim H, Lee J, Lee K, Moon H, Ko E, Kim E, Yu J, Noh D. Value of preoperative staging of breast cancer patients using computed tomography to detect asymptomatic lung and liver metastasis. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.1105] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1105 Background: Preoperative clinical staging in breast cancer patients is important to determine the most appropriate treatment plans and to predict prognosis for individual patients. Identifying unexpected distant metastases in newly diagnosed breast cancer patients frequently alters initial treatment plans. Routine imaging studies to detect lung or liver metastasis is not indicated in patients with early and operable breast cancer. A recent study showed that routine use of chest radiograph and liver ultrasound does not provide much diagnostic benefit in early breast cancer patients. Methods: We aimed to investigate the value of preoperative computed tomography to detect asymptomatic liver and lung metastasis in breast cancer patients. We performed preoperative CT for 667 breast cancer patients to detect lung and liver metastasis among 1,636 primary breast cancer patients who had been diagnosed and treated between January 2006 and December 2007 at Seoul National University Hospital. Results: CT showed abnormal findings (suspicious of metastasis or indeterminate nodules) in 78 patients (10.5%). Among these, abnormal finding in 13 patients (1.7%) turned out to be true metastatic lesions. There was no CT-detected lung or liver metastasis in patients with T1 tumor and 4 metastases in patients with T2 tumor. There was no CT-detected lung or liver metastasis in patients with negative axillary lymph node metastasis. When patients were classified according to the AJCC staging, CT-detected true metastatic lesions were only present in stage III patients (13 out of 173 patients, 7.5%). The true metastatic lesions in lung or liver were all small sized nodules, ranging from 0.3cm to 1.2cm in largest diameters. In seven patients, the CT-detected metastatic lesions were less than 1cm which is in contrast with the previous studies. Conclusions: Our results demonstrated the lack of usefulness in performing routine CT exams to detect asymptomatic liver and lung metastasis in early breast cancer patients. Staging CT might be useful in stage III patients, since 13 (7.5%) patients were upstaged to stage IV by the use of CT. No significant financial relationships to disclose.
Collapse
|
74
|
Tan Y, Han S, Lu Y, Yip CH, Sunpaweravong P, Jeong J, Caguioa PB, Aggarwal S, Yeoh EM, Moon H. Breast cancer ErbB2 status in Asian women: A review of local literature. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e22164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e22164 Background: Breast cancer incidence is increasing throughout Asia. However, the characteristics of Asian breast cancer are not always well understood due to the limited availability of local data and their inadequate inclusion in global literature databases. Effective breast cancer treatment in this region requires a better understanding of Asian breast cancer biology, including ErbB2 status. Methods: We performed a literature search in seven Asian countries on breast cancer studies in which tumour ErbB2 overexpression was assessed. The keywords erbB2 OR HER2 OR ErbB-2 OR HER-2 AND breast cancer AND (country) were used to search PubMed, international and local conference abstracts and local-language journals from the year 2000 onwards. Where available, we selected up to five representative studies from each country on the basis of population size, multi-institution patient populations, institution reputation and journal impact factor. We excluded studies containing only mRNA, serum, or cell line data or those conducted on biased populations or in western countries on Asian populations. Results: ErbB2 data from 26 Asian breast cancer studies are summarized in the table . The mean or median age of the study populations ranged from 46–56 years, with one exception. In most studies that evaluated tumour ErbB2 and hormone status, ErbB2 over-expression correlated negatively with ER positivity. Conclusions: The larger studies in particular confirm that the proportion of ErbB2-positive breast cancer in Asia is generally similar to the 20–30% reported for western women. Definitions of ErbB2 positivity using IHC vary between institutions and FISH is not routinely performed in several Asian countries. This may contribute to the fact that reliable, representative data on breast tumour ErbB2 status is scarce in Malaysia, the Philippines, India and Thailand. The increased availability of accurate ErbB2 testing and data would aid improved treatment of ErbB2-positive breast cancer in these countries. [Table: see text] [Table: see text]
Collapse
|
75
|
Moon H, Han W, Lee J, Ko E, Kim E, Kim E, Yu J, Noh D. Underweight and breast cancer recurrence and death. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e22054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e22054 Background: The association of body mass index or body weight and breast cancer outcome is controversial. Furthermore, the impact of underweight on breast cancer recurrence and death has not been adequately addressed. Methods: We investigated this issue in a large nation-wide database of 14,039 Korean breast cancer patients (Korean Breast Cancer Registry). Furthermore, to test whether the association was due to more frequent non-cancer death in underweight women, we used breast cancer recurrence data of 4,345 women from single institution (Seoul National University Hospital). Results: The results from Korean Breast Cancer Registry data showed significantly lower overall survival in underweight patients compared to normal weight after adjusting known prognostic factors [hazard ratio=1.36 (95% CI 1.08–1.72)], which was not observed in obese patients. The association between body mass index and breast cancer recurrence was further investigated in Seoul National University Hospital data. Underweight women had significantly higher risk of distant metastasis and local recurrence of breast cancer [hazard ratio=1.86 (95% CI 1.25–2.76) and 2.62 (95% CI 1.55–4.41), respectively]. Conclusions: These findings suggest that underweight could be considered as high risk factor of death and recurrence after breast cancer surgery. No significant financial relationships to disclose.
Collapse
|